With just two IPOs, it was the slowest October for the IPO market since 2011, though it was also the first month this year to produce only $100+ million IPOs, as small issuers continued to delay amid rising scrutiny. Intel's driver-assistance tech unit...read more
Prime Medicine, a preclinical biotech developing novel gene editing therapies for various diseases, raised $175 million by offering 10.3 million shares at $17, within the range of $16 to $18. The company offered 1.4 million more shares than anticipated. Prime...read more
A handful of deals are scheduled to price in the week ahead, led by large biotech Prime Medicine (PRME), which would be the first sizable IPO of the fourth quarter. Along with the deals already scheduled, Intel’s...read more
Three SPACs began trading this past week, joined by one micro-cap, though it was too small to be included in our IPO stats. Two small IPOs submitting initial filings. The biggest news came from the pipeline, as gene editing biotech ...read more
Renaissance Capital's October IPO Market Update
With just two IPOs, it was the slowest October for the IPO market since 2011, though it was also the first month this year to produce only $100+ million IPOs, as small issuers continued to delay amid rising scrutiny. Intel's driver-assistance tech unit...read more
Preclinical gene editing biotech Prime Medicine prices upsized IPO at $17 midpoint
Prime Medicine, a preclinical biotech developing novel gene editing therapies for various diseases, raised $175 million by offering 10.3 million shares at $17, within the range of $16 to $18. The company offered 1.4 million more shares than anticipated. Prime...read more
US IPO Week Ahead: Gene editing biotech plots the first $100+ million IPO of the 4Q
A handful of deals are scheduled to price in the week ahead, led by large biotech Prime Medicine (PRME), which would be the first sizable IPO of the fourth quarter. Along with the deals already scheduled, Intel’s...read more
US IPO Weekly Recap: Quiet October continues with micro-caps and SPACs
Three SPACs began trading this past week, joined by one micro-cap, though it was too small to be included in our IPO stats. Two small IPOs submitting initial filings. The biggest news came from the pipeline, as gene editing biotech ...read more